In short
BMS-986470 is a new investigational drug currently being studied for its potential benefits in treating sickle cell disease. This article explores an ongoing Phase 1/2a clinical trial that evaluates this drug in both healthy volunteers and patients with sickle cell disease. The research aims to determine the safety, tolerability, and preliminary effectiveness of BMS-986470, while also studying how the body processes the medication under different conditions. This first-in-human study represents an important step in developing new treatment options for those affected by sickle cell disease.
Key points
- BMS-986470 is currently being investigated in a Phase 1/2a clinical trial to evaluate its potential for treating sickle cell disease. The study includes both healthy volunteers and patients with sickle cell disease and aims to determine the drug's safety profile, how it moves through the body, and preliminary evidence of effectiveness. A key focus is measuring whether BMS-986470 can increase fetal hemoglobin (HbF) levels, which could prevent red blood cells from sickling. The trial is designed with multiple participant groups receiving different dosing regimens, and researchers are tracking various blood markers to understand how the drug affects red blood cell health and function. This research represents an important step in developing new treatment options for sickle cell disease.
At a glance
- Study Type
- Phase 1/2a, first-in-human, randomized, double-blinded, placebo-controlled, dose-finding study
- Study Population
- Healthy volunteers and participants with sickle cell disease
- Drug Being Tested
- BMS-986470 (multiple dosing regimens)
- Primary Outcomes
- Safety measures: adverse events, serious adverse events, dose-limiting toxicities, discontinuations, deaths
- Key Secondary Outcomes
- • Pharmacokinetic parameters (Cmax, AUC, Tmax); • Changes in total hemoglobin and hemoglobin fractions (HbA, HbF, HbS); • Markers of red blood cell destruction; • Number of participants achieving significant HbF increases (≥10%, ≥20%, ≥30%)
- Study Design
- • Multiple cohorts of participants; • Cohort A: Parts 1 and 2 (likely dose escalation); • Cohort B: Parts 1 and 2 (likely extension or specific patient groups); • Includes pH and food effect evaluation
What is BMS-986470?
BMS-986470 is an investigational medication that is being developed for the treatment of sickle cell disease. It is currently in early stages of clinical development (Phase 1/2a trials) which means researchers are studying its safety, how it moves through the body, and whether it might be effective in treating sickle cell disease.
Study Overview
This drug is being evaluated in a "first-in-human" clinical trial, which means this is one of the earliest studies testing this medication in people. The study is designed as a randomized, double-blinded, placebo-controlled, dose-finding study. These terms mean:
- Randomized: Participants are assigned by chance to either receive the actual drug or a placebo (a substance with no active ingredients)
- Double-blinded: Neither the participants nor the researchers know who is receiving the actual drug or placebo
- Placebo-controlled: Some participants receive a placebo to help determine if the drug's effects are real
- Dose-finding: Different amounts of the drug are tested to find the most appropriate dose
The study includes both healthy volunteers and patients with sickle cell disease. This approach is common in early drug development to first establish safety in healthy people before testing in patients with the condition.
Target Conditions: Sickle Cell Disease
Sickle cell disease is an inherited blood disorder that affects the shape of red blood cells. In this condition, red blood cells become shaped like crescents or sickles instead of the normal disc shape. These abnormally shaped cells can get stuck in small blood vessels, causing pain, organ damage, and other serious complications. The disease also causes hemolytic anemia, a condition where red blood cells break down prematurely.
A key feature of the disease is the presence of sickle hemoglobin (HbS), which is different from normal adult hemoglobin (HbA). Hemoglobin is the protein in red blood cells that carries oxygen. Another type of hemoglobin, fetal hemoglobin (HbF), is normally produced during fetal development but production decreases after birth. Increasing HbF levels can help reduce symptoms in sickle cell disease patients.
How the Drug Works
While the exact mechanism of BMS-986470 isn't explicitly stated in the study information, the study's measures suggest that the drug may work by affecting hemoglobin production. Specifically, one of the goals appears to be increasing the production of fetal hemoglobin (HbF). This is an important potential treatment approach because fetal hemoglobin can prevent or reduce the sickling of red blood cells that occurs with sickle hemoglobin (HbS).
The study is measuring changes in different hemoglobin types, including HbF, HbA, and HbS, which suggests that the drug may alter the balance of these hemoglobins in the body.
Safety and Monitoring
As with all experimental medications, safety is a primary concern. The study is carefully monitoring for:
- Adverse events (AEs): Any undesirable experience that occurs during the study
- Serious adverse events (SAEs): Events that may be life-threatening or require hospitalization
- Dose Limiting Toxicity (DLT): Side effects serious enough to prevent increasing the dose further
- Events leading to discontinuation of the treatment
- Any deaths that occur during the study
The study is also examining how the drug moves through the body (pharmacokinetics) and how it affects the body (pharmacodynamics). Researchers are also looking at how food and stomach pH (acidity) might affect how the drug works.
Effectiveness Measures
To determine if BMS-986470 might be effective for sickle cell disease, researchers are measuring several indicators:
- Hemoglobin levels: Checking if total hemoglobin increases, which could improve oxygen delivery to tissues
- Hemoglobin fractions: Measuring changes in different types of hemoglobin (HbA, HbF, HbS)
- Red blood cell (RBC) lysis markers: Monitoring indicators that show whether red blood cells are breaking down less frequently, including:
- Aspartate aminotransferase (AST): An enzyme that increases when cells are damaged
- Lactate dehydrogenase (LDH): Another enzyme that increases with cell damage
- Bilirubin: A yellowish substance produced when red blood cells break down
- Haptoglobin: A protein that binds to hemoglobin released from damaged red blood cells
- Reticulocyte count: Immature red blood cells; high counts can indicate the body is trying to compensate for anemia
- Schistocyte count: Fragmented red blood cells that can indicate damage
The study is particularly interested in how many participants achieve specific HbF levels (10%, 20%, or 30% or more). Higher levels of HbF are generally associated with less severe sickle cell disease symptoms.
Potential Benefits for Patients
If successful, BMS-986470 could potentially offer several benefits for sickle cell disease patients:
- Increased fetal hemoglobin: By potentially increasing HbF levels, the drug might reduce the sickling of red blood cells
- Reduced cell destruction: Less breaking down of red blood cells could mean less anemia and fewer complications
- Improved hemoglobin levels: Higher total hemoglobin could improve oxygen delivery throughout the body
- Fewer pain crises: With less sickling and vessel blockage, patients might experience fewer painful episodes
It's important to note that since this is an early-phase clinical trial, the effectiveness of BMS-986470 is still being investigated, and it may be several years before the drug could potentially become available as an approved treatment.